NCT03633058View on ClinicalTrials.gov

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

November 8, 2021

Study Completion Date

November 22, 2021

Conditions
Rett Syndrome
Interventions
DRUG

Ketamine

oral ketamine dosed twice daily for 5 days

Trial Locations (7)

19104

Children's Hospital of Philadelphia, Philadelphia

35294

University of Alabama Birmingham School of Medicine, Birmingham

37203

Vanderbilt University Medical Center, Nashville

60612

Rush University Medical Center, Chicago

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

02115

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

lead

Rett Syndrome Research Trust

OTHER

NCT03633058 - A Study to Evaluate Ketamine for the Treatment of Rett Syndrome | Biotech Hunter | Biotech Hunter